Last month, Vancouver-based Optimi Health launched an initial public offering of 2.5 million shares, capitalizing on a rapid surge in U.S. policy and cultural support for psychedelic drugs. The move came after President Donald Trump’s executive order easing restrictions on psychedelics, reportedly influenced by podcaster Joe Rogan. Optimi manufactures natural psilocybin and MDMA, both FDA-designated breakthrough therapies, from two 10,000-square-foot GMP-certified facilities in Princeton, British Columbia. The company, a self-described “specialty CDMO,” produces roughly two million capsules a year, serving over 200,000 patients. MDMA and psilocybin capsules are priced at $33.33 and $20 respectively. Already supplying Australia’s reclassified market, Optimi sells directly to pharmacies instead of through intermediaries, which CEO Dane Stevens said keeps costs lean and margins healthy.
The IPO arrives at a transitional moment for psychedelic therapeutics. If federal easing in the U.S. mirrors Australia’s 2023 policy shift, manufacturers like Optimi will see orders multiply almost overnight. The firm’s GMP certification and manufacturing-only structure mark a deliberate break from vertically integrated startups, it’s infrastructure, not ideology. Investors view Optimi as a contract producer positioned to scale with research demand, more like the early cannabinoid processors than the newer biotech hopefuls. The ability to price aggressively while retaining distribution control gives the company unusual leverage in a supply chain that regulators and payer programs are just beginning to map. Frankly, that’s rare at this stage of a market’s build-out.
More broadly, psychedelics are stepping out of fringe science and into policy-backed therapeutics. If coverage frameworks resembling Australia’s veteran PTSD program take hold in the U.S., procurement standards and reimbursement models will follow through specialty pharmacy channels. That shift would push PBMs and benefit managers to define formulary inclusion and sourcing rules faster than their current timelines suggest, and few seem ready. For a deeper look at PBM-side benchmarking and contracting, see RxPBM.ai. Nobody can say precisely how fast this realignment goes. But once federal coverage discussions begin, the change tends to move all at once. Then everyone scrambles.
